Structure-based classification predicts drug response in EGFR-mutant NSCLC.

ABSTRACT: Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18-21 and are established driver mutations in non-small cell lung cancer (NSCLC)^1-3. Targeted therapies are approved for patients with 'classical' mutations and a small number of other mutations^4-6. However, effective therapies have not been identified for additional EGFR mutations. Furthermore, the frequency and effects of atypical EGFR mutations on drug sensitivity are unknown^1,3,7-10. Here we characterize the mutational landscape in 16,715 patients with EGFR-mutant NSCLC, and establish the structure-function relationship of EGFR mutations on drug sensitivity. We found that EGFR mutations can be separated into four distinct subgroups on the basis of sensitivity and structural chang

SUBMITTER: Robichaux JP 

PROVIDER: S-EPMC8481125 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature